Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Jounce Therapeutics Inc (JNCE) USD0.001

Sell:$9.00 Buy:$9.01 Change: $0.17 (1.93%)
NASDAQ:0.64%
Market closed |  Prices as at close on 27 October 2020 | Switch to live prices |
Sell:$9.00
Buy:$9.01
Change: $0.17 (1.93%)
Market closed |  Prices as at close on 27 October 2020 | Switch to live prices |
Sell:$9.00
Buy:$9.01
Change: $0.17 (1.93%)
Market closed |  Prices as at close on 27 October 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. The Company’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates Inducible T cell CO-Stimulator (ICOS) and is in a Phase II trial.

Contact details

Address:
780 Memorial Dr
CAMBRIDGE
02139-4613
United States
Telephone:
+1 (857) 2593840
Website:
jouncetx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
JNCE
ISIN:
US4811161011
Market cap:
$307.93 million
Shares in issue:
34.21 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Perry Karsen
    Independent Chairman of the Board
  • Richard Murray
    President, Chief Executive Officer, Director
  • Kimberlee Drapkin
    Chief Financial Officer, Treasurer
  • Hugh Cole
    Chief Business Officer, Head of Corporate Development
  • Elizabeth Trehu
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.